 | Elizabeth A EisenhauerShow email addressDepartment of Oncology, Queen's University, Kingston, Canada | Department of Oncology, Queen's University, Kingston, ON, Canada. | Department of Oncology, School of Medicine, ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Elizabeth A Eisenhauer:Expert Impact
Concepts for whichElizabeth A Eisenhauerhas direct influence:National cancer institute,Ovarian cancer,Canada clinical trials,Ncic ctg,Task force,Ncic clinical trials.
Elizabeth A Eisenhauer:KOL impact
Concepts related to the work of other authors for whichfor which Elizabeth A Eisenhauer has influence:Ovarian cancer,Cell lung,Neoadjuvant chemotherapy,Solid tumors,Antineoplastic agents,Glioblastoma multiforme,Elderly patients.
KOL Resume for Elizabeth A Eisenhauer
| Year | |
|---|---|
| 2022 | Department of Oncology, Queen's University, Kingston, Canada |
| 2021 | Departments of Oncology, Queen’s University, Kingston, Canada |
| 2020 | Queen's University, Kingston, Canada |
| 2018 | Department of Oncology, Queen's University, Kingston, Ontario, Canada |
| 2017 | Department of Oncology, Queen's University, Kingston Health Sciences Centre, Kingston, Canada. Canadian Cancer Trials Group (CCTG), Queen’s University, Kingston, Canada; Queen’s University and Cancer Centre of South Eastern Ontario at Kingston General Hospital, Kingston, ON Canada |
| 2016 | Canadian Cancer Trials Group (CCTG) and Queen's University, Kingston, ON, Canada Department of Oncology, Queen's University, Kingston, ON. |
| 2015 | NCIC Clinical Trials Group, Kingston, ON, Canada |
| 2014 | NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada |
| 2013 | NCIC Clinical Trials Group, Queen's University, 10 Stuart St, Kingston, Ontario K7L 3N6, Canada |
| 2012 | Department of Medical Oncology, Queen's University, Kingston, Canada NCIC Clinical Trials Group, Kingston, Ontario |
| 2011 | NCIC Clinical Trials Group, Queen's University, Kingston, Ontario National Cancer Institute of Canada Clinical Trials Group, Queen’s University, Kingston, Canada S, *, BIO Pte Ltd, 1 Science Park Road, #05-09 The Capricorn, Singapore Science Park II, 117 528, Singapore |
| 2010 | National Cancer Institute of Canada Clinical Trials Group, Kingston University of Montreal, Montreal, Quebec, Canada Tom Baker Cancer Centre, Calgary Princess Margaret Hospital, Toronto, Ontario Vancouver Prostate Centre, Vancouver, British Columbia |
| 2009 | and Saitama Medical University, Hidaka City, Saitama, Japan. National Cancer Institue of Canada, Clinical Trials Group, Kingston, Ontario, Canada University of New South Wales, Sydney, New South Wales, Australia GlaxoSmithKline Biologicals, Rixensart, Belgium Medical Research Council Clinical Trials Unit, London |
| 2008 | From the Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD and Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA National Cancer Institute of Cancer Clinical Trials Group, Queen's University, Kingston, Ontario, Canada Southwest Oncology Group Statistical Office, Seattle, WA Peace Corps, Washington, DC |
| 2007 | Eastern Cooperative Oncology Group, Philadelphia, PA NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada. National Cancer Institute of Canada Clinical Trials Group, Queen’s University, 10 Stuart Street, Kingston, ON, Canada K7L 3N6 Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia From the Princess Margaret Hospital, Toronto |
| Concept | World rank |
|---|---|
| oral pracinostat tiw | #1 |
| small cell deoxycytidine | #1 |
| topic recist | #1 |
| ncicctg antineoplastic agents | #1 |
| 83 116 cycles | #1 |
| tumourcentred definition 95 | #1 |
| ly293111 dlt | #1 |
| trials cytotoxic | #1 |
| toxicity drug dose | #1 |
| response pten | #1 |
| toxicity treatment discontinuation | #1 |
| letrozole disease progression | #1 |
| studies canadian sarcoma | #1 |
| phase osi211 | #1 |
| sb939 objective responses | #1 |
| curve dna cytosine5methyltransferase | #1 |
| cycles sequential couplets | #1 |
| teloxantrone | #1 |
| cisplatin arm cyclophosphamide | #1 |
| reporting benefit | #1 |
| dose levels dlt | #1 |
| ca125 progression endpoint | #1 |
| women toxic effects | #1 |
| cyclophosphamide cisplatin arm | #1 |
| strict progression | #1 |
| trimetrexate malignant melanoma | #1 |
| 45 adult dose | #1 |
| cohort 30 μg | #1 |
| response evaluation model | #1 |
| continual validation | #1 |
| rpr 109881a | #1 |
| non‐cytotoxics | #1 |
| schedule osi211 | #1 |
| dlt doses | #1 |
| solid tumors guidelines | #1 |
| response preliminary | #1 |
| cancer treatment oncology | #1 |
| menogaril dose 225 | #1 |
| amsterdam phase | #1 |
| 265months | #1 |
| myeloma indolent lymphomas | #1 |
| doselimiting toxicity acivicin | #1 |
| cb endpoint | #1 |
| ncic ind161 | #1 |
| everolimus tmz | #1 |
| 225 4 | #1 |
| rptd 5 consecutive | #1 |
| chose trade | #1 |
| definition toxicity | #1 |
| 1 sb939 | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by Elizabeth A Eisenhauer
BACKGROUND: Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1-3 inhibitor that has shown antitumour activity in recurrent ovarian cancer. We assessed efficacy and safety of cediranib in combination with platinum-based chemotherapy and as continued maintenance treatment in patients with first relapse of platinum-sensitive ovarian cancer.
METHODS: In this randomised, ...
| Known for Ovarian Cancer | 3 Trial | Chemotherapy Cediranib | Arm Maintenance | Local Neoplasms |
BACKGROUND: A randomised trial published by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group (trial 26981-22981/CE.3) showed that addition of temozolomide to radiotherapy in the treatment of patients with newly diagnosed glioblastoma significantly improved survival. We aimed to undertake an exploratory subanalysis of the EORTC and NCIC data to confirm or identify new prognostic factors for ...
| Known for Radiotherapy Temozolomide | Ncic Trial | Newly Diagnosed Glioblastoma | Performance Status | Combined Treatment |
BACKGROUND: In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy. We report the final results with a median follow-up of more than 5 years.
METHODS: Adult patients with newly diagnosed glioblastoma were randomly assigned ...
| Known for Adjuvant Temozolomide | 5 Years | Radiotherapy Survival | Eortc Ncic | Phase Iii |
BACKGROUND: Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination compared with standard frontline therapy.
METHODS: Women aged 75 years or younger with newly diagnosed stage IIB or greater ovarian cancer, Eastern Cooperative Oncology Group Performance Status of 1 or less, were stratified by type of primary surgery and residual disease, treatment center, and age; then randomly assigned to one of the two 21-day intravenous regimens. ...
| Known for Paclitaxel Carboplatin | Advanced Ovarian Cancer | Patients Arm | Neoplasm Female Humans | Phase Iii |
BACKGROUND: Early endometrial cancer with low-risk pathological features can be successfully treated by surgery alone. External beam radiotherapy added to surgery has been investigated in several small trials, which have mainly included women at intermediate risk of recurrence. In these trials, postoperative radiotherapy has been shown to reduce the risk of isolated local recurrence but there is no evidence that it improves recurrence-free or overall survival. We report the findings from ...
| Known for External Beam Radiotherapy | Endometrial Cancer | Ncic Ctg | Mrc Astec | Intermediate Risk |
PURPOSE: Most patients with advanced ovarian cancer develop recurrent disease. For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel; however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation. Thus, an alternative regimen without significant neurotoxicity was evaluated by comparing gemcitabine plus carboplatin with ...
| Known for Carboplatin Patients | Sensitive Recurrent | Ovarian Cancer | Ncic Ctg | Quality Life |
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
[ PUBLICATION ]
BACKGROUND: Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials. Since RECIST was published in 2000, many investigators, cooperative groups, industry and government authorities have adopted these criteria in the assessment of treatment outcomes. However, a number of questions and issues have arisen which have led to ...
| Known for Revised Recist | New Response | Tumour Burden | Sum Lesions | Special Issue |
BACKGROUND: Pemetrexed disodium (Alimta [Eli Lilly and Company, Indianapolis, IN], LY231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. Phase II trials showed single-agent response rates of 16% and 23% in untreated patients with nonsmall cell lung carcinoma (NSCLC). This study was undertaken to determine the response to pemetrexed disodium given in combination with cisplatin.
METHODS: Previously untreated ...
| Known for Pemetrexed Disodium | Multitargeted Antifolate | Performance Status | Cell Lung | Nsclc Study |
AIM: The impact of PTEN status and microsatellite instability (MSI) on the prognosis of women with endometrial cancer is controversial. The aim of this study was to investigate MSI and PTEN expression in two patient populations using data from NCIC CTG studies.
METHODS: Archival paraffin embedded tumour from women with endometrial cancer enrolled in NCIC CTG studies: EN5 (stage I/II) and IND 126, 148 and 160 (advanced/recurrent disease) were examined for MSI using BAT25/26 and for PTEN ...
| Known for Microsatellite Instability | Pten Expression | Endometrial Cancer | Msi Status | Ncic Clinical Trials |
BACKGROUND: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety.
METHODS: Patients with newly diagnosed, histologically confirmed glioblastoma were ...
| Known for Adjuvant Temozolomide | Patients Radiotherapy | 5 Week | Square Meter | Primary Point |
Prolonged exposure to a topoisomerase I inhibitor may increase expression of topoisomerase II, making cells more susceptible inhibitors of that enzyme. This study was undertaken to establish the maximum tolerated dose (MTD) of a topotecan/topoisomerase II inhibitor sequential combination that may be active in acute leukemia, and to evaluate the effects of in vivo exposure to topotecan on topoisomerase II levels in leukemic blast cells as measured by image cytometry. Patients who were ...
| Known for Sequential Topotecan | Acute Leukemia | National Cancer Institute | Patients Phase | Dose Levels |
Health-related quality of life in patients with glioblastoma: a randomised controlled trial
[ PUBLICATION ]
BACKGROUND: A randomised controlled trial of radiotherapy alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma showed that survival was higher for patients assigned combination treatment compared with those assigned standard radiotherapy alone. This paper reports the health-related quality of life (HRQOL) of the patients in this trial.
METHODS: 573 patients with newly diagnosed glioblastoma were randomly allocated either radiotherapy alone ...
| Known for Radiotherapy Patients | Life Hrqol | Controlled Trial | Healthrelated Quality | Newly Diagnosed Glioblastoma |
BACKGROUND: Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment resistance. OGX-011 is a 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA and has been reported to inhibit clusterin expression and enhance drug efficacy in xenograft models. The primary objective of this clinical study was to determine a biologically effective dose of OGX-011 that would inhibit clusterin ...
| Known for Localized Prostate Cancer | Clusterin Expression | Pharmacodynamic Study | Antisense Oligonucleotide | Dose Ogx011 |
PURPOSE: Formal quality-of-life (QOL) assessments may contribute important information on patient symptoms. Despite many trials of systemic chemotherapy in ovarian cancer, reports of its effect on QOL are few.
PATIENTS AND METHODS: QOL was assessed in an Intergroup randomized trial comparing paclitaxel plus cisplatin to cyclophosphamide plus cisplatin in women with advanced ovarian cancer. One hundred fifty-two eligible patients accrued in Canada completed the European Organization for ...
| Known for Ovarian Cancer | Paclitaxel Cisplatin | Qol Patients | Quality Life | European Organization |
